Furthermore, the expression of PDE5 was reported to increase in the hypertrophied RV compared with the normal RV both in PAH patients and MCT-induced PAH rat models [155], indicating that cardiac pharmacodynamics may also account for the therapeutic action of PDE5i. Here, PDE5A is linked to pulmonary arterial hypertension.